Pilocarpine is a direct-acting parasympathomimetic agent that works by stimulating muscarinic acetylcholine receptors. It mimics acetylcholine, the natural neurotransmitter in the parasympathetic nervous system, to trigger responses in target organs like the eyes and salivary glands.
Cellular and Subtype Specificity
Pilocarpine activates muscarinic receptors (M1–M5), but its main effects come from stimulating the M3 subtype. M3 receptors are common in smooth muscles of the eye and in glands such as salivary, sweat, and tear glands. When pilocarpine binds to M3 receptors, it activates a Gq-protein pathway, leading to the production of $IP_3$ and $DAG$. This process increases intracellular calcium, which causes smooth muscle contraction and glandular secretion.
Ocular Effects: Glaucoma and Presbyopia
Pilocarpine's action in the eye is key for treating glaucoma and presbyopia.
Contraction of the Iris Sphincter Muscle
Pilocarpine makes the iris sphincter muscle contract, causing the pupil to become smaller (miosis). This can help in conditions like acute angle-closure glaucoma by opening the drainage angle of the eye.
Contraction of the Ciliary Muscle
Contraction of the ciliary muscle is a significant effect of pilocarpine.
- Glaucoma: This contraction pulls on the scleral spur, which opens the trabecular meshwork. This increases the flow of fluid out of the eye, reducing intraocular pressure (IOP).
- Presbyopia: Ciliary muscle contraction also changes the shape and position of the eye's lens. This enhances the eye's depth of focus, improving near vision for people with age-related blurry near vision.
Glandular Effects: Xerostomia
In addition to eye treatments, pilocarpine is used orally to treat dry mouth (xerostomia), which can be caused by radiotherapy or Sjögren's syndrome.
Stimulation of Exocrine Glands
When taken by mouth, pilocarpine stimulates muscarinic receptors, mainly M3, on salivary gland cells. This results in a large increase in saliva production.
Comparison with Other Cholinergic Drugs
Pilocarpine's actions and side effects differ from other cholinergic medications like cevimeline (for dry mouth) and bethanechol (for urinary retention).
Feature | Pilocarpine | Bethanechol | Cevimeline |
---|---|---|---|
Primary Use | Dry mouth (xerostomia), glaucoma, presbyopia | Urinary retention | Dry mouth (xerostomia) |
Receptor Action | Non-selective muscarinic agonist (primary M3 effects) | Primarily muscarinic agonist (M3, M2) | Selective muscarinic agonist (M3) |
Adverse Effects | Sweating, flushing, nausea, vision changes, headache | Gastrointestinal upset, urinary frequency, flushing, bradycardia | Sweating, nausea, flushing, diarrhea |
Route of Administration | Oral (tablets), Ophthalmic (drops) | Oral (tablets) | Oral (capsules) |
Signal Transduction Pathway
The signaling pathway for pilocarpine involves these key steps:
- Receptor Binding: Pilocarpine binds to M3 muscarinic receptors.
- Gq Protein Activation: This activates a Gq-protein.
- PLC Stimulation: The Gq-protein activates PLCβ.
- PIP2 Hydrolysis: PLCβ breaks down PIP2 into $IP_3$ and $DAG$.
- Calcium Release: $IP_3$ causes calcium to be released from storage inside the cell.
- Physiological Response: Increased calcium leads to effects like muscle contraction or gland secretion.
Conclusion
Pilocarpine works by stimulating muscarinic receptors, like acetylcholine, to increase intracellular calcium. This action causes smooth muscles to contract and glands to secrete fluids. This mechanism makes it useful for treating conditions such as glaucoma, presbyopia, and dry mouth.
Visit a resource for further information on cholinergic pharmacology.